MELBOURNE, Australia, April 15 /PRNewswire/ -- Cytopia Limited (ASX: CYT) announced that it will present data on its anticancer vascular disrupting agent (VDA) CYT997 at the forthcoming 100th Annual Meeting of the American Association for Cancer Research, in Denver, Colorado, USA.
Dr David Segal, Principal Scientist at Cytopia, will be presenting the poster in the Late-Breaking Research: Experimental and Molecular Therapeutics 2 poster session on Tuesday, April 21, 2009 from 8:00 AM to 2:00 PM (US MDT), Hall BF, Poster Section 26, Poster Board 18.
The poster, entitled CYT997: Preclinical studies on the antivascular effects and mode of action of a Phase II vascular disrupting agent outlines extensive preclinical data for CYT997 which is currently in Phase II clinical studies. Data for CYT997 in a panel of in vitro and in vivo assays will be shown clearly demonstrating the potent antivascular and cytotoxic effects of the compound.
Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.
The company's lead drug candidate is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, which is currently being trialed in Phase II clinical studies. Cytopia is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009.
|SOURCE Cytopia Limited|
Copyright©2009 PR Newswire.
All rights reserved